Lifeline for cancer patients: continued access to promising drug olaparib

NCT ID NCT04421963

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study offers continued treatment with the drug olaparib to people with ovarian or breast cancer who have already seen benefits from it in a previous study. The goal is to keep providing the drug safely while monitoring for any serious side effects. About 185 participants will take part, and the study is for those whose doctors agree they are still benefiting from the treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

185 people

The number who actually took part.

Started

Aug 2020

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Provision of signed and dated, written ICF. 2. Patient is currently deriving clinical benefit, as judged by the Investigator, from continued treatment in an AZ parent study using an AstraZeneca (AZ) compound that has met its endpoints or has otherwise stopped. 3. Patient participating in a prior oncology study with an AZ compound in which they received olaparib and are continuing to receive clinical benefit from treatment; the prior study can be an open-label or blinded study, with unblinding at study close. Exclusion Criteria: 1. Ongoing, unresolved, Grade 3 or above toxicity requiring interruption of treatment at the time of the termination of the parent study. 2. Currently receiving treatment with any prohibited medication(s). 3. Concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study. 4. Permanent discontinuation from the parent study due to toxicity or disease progression. 5. Local access to commercially-available drug at no cost to the patient is permitted by local regulation.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast neoplasm neoplasm ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Breast cancer Ovarian cancer

Contacts and locations

Locations

Research Site

Boca Raton, Florida, 33486, United States
Research Site

Towson, Maryland, 21204, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

Minneapolis, Minnesota, 55407, United States
Research Site

Basking Ridge, New Jersey, 07920, United States
Research Site

Hackensack, New Jersey, 07601, United States
Research Site

New York, New York, 10032, United States
Research Site

The Bronx, New York, 10461, United States
Research Site

Philadelphia, Pennsylvania, 19104, United States
Research Site

Pittsburgh, Pennsylvania, 15224, United States
Research Site

Willow Grove, Pennsylvania, 19090, United States
Research Site

Providence, Rhode Island, 02905, United States
Research Site

Germantown, Tennessee, 38138, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Leuven, 3000, Belgium
Research Site

Plovdiv, 4000, Bulgaria
Research Site

Plovdiv, 4004, Bulgaria
Research Site

Sofia, 1330, Bulgaria
Research Site

Halifax, Nova Scotia, B3H 1V7, Canada
Research Site

Kingston, Ontario, K7L 2V7, Canada
Research Site

Mississauga, Ontario, L5M 2N1, Canada
Research Site

Ottawa, Ontario, K1H 8L6, Canada
Research Site

Toronto, Ontario, M4N 3M5, Canada
Research Site

Toronto, Ontario, M5G 2M9, Canada
Research Site

Montreal, Quebec, H1T 2M4, Canada
Research Site

Montreal, Quebec, H2X 0A9, Canada
Research Site

Montreal, Quebec, H3T 1E2, Canada
Research Site

Montreal, Quebec, H4A-3J1, Canada
Research Site

Québec, Quebec, G1S 4L8, Canada
Research Site

Changchun, 130021, China
Research Site

Brno, 625 00, Czechia
Research Site

Brno, 656 53, Czechia
Research Site

Olomouc, 779 00, Czechia
Research Site

Ostrava Poruba, 708 52, Czechia
Research Site

Prague, 128 08, Czechia
Research Site

Prague, 150 06, Czechia
Research Site

Aalborg, 9000, Denmark
Research Site

Kuopio, 70210, Finland
Research Site

Lille, 59020, France
Research Site

Lyon, 69373, France
Research Site

Plérin, 22190, France
Research Site

Villejuif, 94800, France
Research Site

Dresden, 1307, Germany
Research Site

Budapest, 1032, Hungary
Research Site

Budapest, 1122, Hungary
Research Site

Haifa, 31096, Israel
Research Site

Jerusalem, 91031, Israel
Research Site

Jerusalem, 91120, Israel
Research Site

Petah Tikva, 49100, Israel
Research Site

Ramat Gan, 5265601, Israel
Research Site

Tel Aviv, 6423906, Israel
Research Site

Ancona, 60020, Italy
Research Site

Bologna, 40138, Italy
Research Site

Brescia, 25123, Italy
Research Site

Candiolo, 10060, Italy
Research Site

Catania, 95126, Italy
Research Site

Lecce, 73100, Italy
Research Site

Lecco, 23900, Italy
Research Site

Milan, 20132, Italy
Research Site

Milan, 20141, Italy
Research Site

Naples, 80131, Italy
Research Site

Padova, 35128, Italy
Research Site

Roma, 00168, Italy
Research Site

Torino, 10128, Italy
Research Site

Verona, 37134, Italy
Research Site

Bialystok, 15-027, Poland
Research Site

Grzepnica, 72-003, Poland
Research Site

Lublin, 20-090, Poland
Research Site

Olsztyn, 10-561, Poland
Research Site

Poznan, 60-569, Poland
Research Site

Poznan, 61-866, Poland
Research Site

Lisbon, 1649-035, Portugal
Research Site

Porto, 4200-072, Portugal
Research Site

Saint Petersburg, 197758, Russia
Research Site

Ljubljana, 1000, Slovenia
Research Site

Seoul, 01812, South Korea
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06273, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 6351, South Korea
Research Site

Badalona, 08916, Spain
Research Site

Barcelona, 08035, Spain
Research Site

Barcelona, 8907, Spain
Research Site

Barcelona, ?08041, Spain
Research Site

Córdoba, 14004, Spain
Research Site

Donostia / San Sebastian, 20014, Spain
Research Site

Granada, 18014, Spain
Research Site

Madrid, 28027, Spain
Research Site

Madrid, 28041, Spain
Research Site

Madrid, 28046, Spain
Research Site

Pamplona, 31008, Spain
Research Site

Valencia, 46026, Spain
Research Site

Vigo, 36312, Spain
Research Site

Zaragoza, 50009, Spain
Research Site

Lund, 22185, Sweden
Research Site

Taipei, 112, Taiwan
Research Site

Ankara, 06230, Turkey (Türkiye)
Research Site

Istanbul, 34093, Turkey (Türkiye)
Research Site

Şahinbey, 27310, Turkey (Türkiye)
Research Site

Birmingham, B18 7QH, United Kingdom
Research Site

Edinburgh, EH4 2XU, United Kingdom
Research Site

Glasgow, G12 OYN, United Kingdom
Research Site

Hull, HU16 5JQ, United Kingdom
Research Site

London, SW3 6JJ, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Taunton, TA1 5DA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.